NCT00464308View on ClinicalTrials.gov

A Study to Compare the Number of Patients With Gastro-Oesophageal Reflux Disease (GORD) Achieving Heartburn and Regurgitation Symptom Resolution After Treatment With Either Rabeprazole Sodium 20mg, Esomeprazole 20mg or Esomeprazole 40mg

PHASE4CompletedINTERVENTIONAL
Enrollment

1,392

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

May 31, 2008

Study Completion Date

May 31, 2008

Conditions
Gastro-oesophageal Reflux
Interventions
DRUG

Esomeprazole

20mg once daily for 28days - 1 placebo tab/cap \& 1 active tab/cap daily

DRUG

Rabeprazole

20mg once daily for 28days - 1 placebo tab/cap \& 1 active tab/cap daily

DRUG

Esomeprazole

40mg once daily for 28days - 1 placebo tab/cap \& 1 active tab/cap daily

Trial Locations (25)

Unknown

Belconnen

Bondi Junction

Brookvale

Browns Plains

Campbelltown

Campsie

Caringbah

Castle Hill

Charlestown

Dapto

Darlinghurst

Dubbo

Elizabeth

Fairfield

Hoppers Crossing

Ingleburn

Leichhardt

Maroubra

Melton

Mount Druitt

Oaklands Park

Royal Park

Sydney

Wentworthville

Wyoming

All Listed Sponsors
lead

Janssen-Cilag Pty Ltd

INDUSTRY

NCT00464308 - A Study to Compare the Number of Patients With Gastro-Oesophageal Reflux Disease (GORD) Achieving Heartburn and Regurgitation Symptom Resolution After Treatment With Either Rabeprazole Sodium 20mg, Esomeprazole 20mg or Esomeprazole 40mg | Biotech Hunter | Biotech Hunter